Search
Relebactam
go.drugbank.com/drugs/DB12377ApprovedInvestigational[A181195,A181207] It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. … [label] It is considered to be a last-line treatment option and gained FDA approval as part of the combination product RecarbrioⓇ in July 2019.[L7568]
Tamoxifen
go.drugbank.com/drugs/DB00675ApprovedInvestigational[A1026] Tamoxifen was granted FDA approval on 30 December 1977.[L7799] … Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.
Categories: UGT2B7 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexInternational brands: Nolvadex-DVandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalOn April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. … Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexCarfilzomib
go.drugbank.com/drugs/DB08889ApprovedInvestigationalChemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. … FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Categories: P-glycoprotein substrates with a Narrow Therapeutic IndexDexfenfluramine
go.drugbank.com/drugs/DB01191ApprovedIllicitWithdrawnFor a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. … Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug.
Synonyms: d-N-ethyl-α-methyl-m-trifluoromethylphenethylamineErtugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigational[A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621] … Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus.
Pipamperone
go.drugbank.com/drugs/DB09286InvestigationalPipamperone is a typical antipsychotic of the _butyrophenone_ family used in the treatment of schizophrenia. … Interestingly, when [risperidone] was created, Janssen suggested it was a more potent version of pipamperone.
Categories: Dopamine D2 Receptor AntagonistsChlorpromazine
go.drugbank.com/drugs/DB00477ApprovedInvestigationalVet approvedThe prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has s...
Categories: Dopamine D2 Receptor AntagonistsDaprodustat
go.drugbank.com/drugs/DB11682ApprovedInvestigationalDaprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK. … As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces erythropoiesis.
Lisdexamfetamine
go.drugbank.com/drugs/DB01255ApprovedInvestigationalLisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine,[A40246] covalently attached to the naturally occurring amino acid L-lysine. … [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009.